Piflufolastat: all 30 studies that test it
Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Ultralow Dose PET Imaging for PSMA ExpressionRecruitingNCT06904313Phase 2
- Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide TetraxetanRecruitingNCT06099093Phase 4
- Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal TherapyRecruitingNCT05919329Phase 4
- 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation TherapyRecruitingNCT05155046Phase 2
- Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CTRecruitingNCT03861676Early Phase 1
- Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical ProstatectomyCompletedNCT06604442Phase 4Results posted
- 18F-DCFPyL PET/CT in Hepatocellular CarcinomaTerminatedNCT05009979Phase 2Results posted
- 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate CancerTerminatedNCT04727736Phase 2Results posted
- 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate CancerCompletedNCT04390880Phase 2Results posted
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerCompletedNCT03739684Phase 3Results posted
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerCompletedNCT02981368Phase 2/3Results posted
- Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell CarcinomaCompletedNCT02687139Not applicableResults posted
- Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical ProstatectomyCompletedNCT02523924Not applicableResults posted
- Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCCWithdrawnNCT07084909Phase 2/3
- PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate CancerActive, not recruitingNCT06074510Phase 4
- Prostate MRI and Pylarify PSMA PET/CTWithdrawnNCT05568537Phase 4
- A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast CancerActive, not recruitingNCT05394259Phase 1
- PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate CancerWithdrawnNCT04910425Phase 2
- Evaluation of PSMA in HER2- AR+ Metastatic Breast CancerCompletedNCT04573231Phase 2
- Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate CancerCompletedNCT03860987Phase 2
- 18F-DCFPyL PET-CT Scan and Prostate CancerStatus unknownNCT03852654Phase 2/3
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerWithdrawnNCT03800784Phase 2/3
- Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate CancerCompletedNCT03793543Phase 1
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based BiomarkersActive, not recruitingNCT03585114Phase 2
- Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.CompletedNCT03497377Phase 1
- Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate CancerActive, not recruitingNCT03471650Phase 2
- 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerActive, not recruitingNCT03181867Phase 2
- 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate CancerActive, not recruitingNCT03173924Phase 2
- Integrated 18F-labelled PSMA ProjectStatus unknownNCT02691169Early Phase 1
- Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate CancerCompletedNCT02151760Phase 1